47. D.Q. Ma et al., "New Injectable Melphalan Formulations Utilizing (SBE)7m-[beta]-CD or HP-[beta]-CD," Int. J. Pharm.
189 (2), 227–234 (1999).
48. D.L. Teagarden and D. S. Baker, "Practical Aspects of Lyophilization Using Nonaqueous Cosolvent Systems," Eur. J. Pharm. Sci.
15 (2), 115–133 (2002).
49. M.E. Brewster et al., "Effect of Various Cyclodextrins on Solution Stability and Dissolution Rate of Doxorubicin Hydrochloride,"
Int. J. Pharm.
79 (1–3), 289–299 (1992).
50. P.P. Deluca and J.C. Boylan, Formulation of Small-Volume Parenterals, K.E. Avis et al. Eds. (Marcel Dekker Inc.,New York, NY 1992), pp.180–182.
51. H.R. Costantino et al., "Deterioration of Lyophilized Pharmaceutical Proteins," Biochemistry
63 (3), 357–422 (1998).
52. A.D. Kanavage et al., "Resistance of Antivenom Proteins to Foaming-Induced Denaturation," Toxicon
47 (4), 445–452 (2006).
53. "Guidelines for the Reconstitution of Synagis® (palivizumab),"
http://www.synagis.com/hcp/pdf/SSP04%20072.pdf, accessed July 13, 2006.
54. T.P. Kravtchenko et al., "A Novel Method for Determining the Dissolution Kinetics of Hydrocolloid Powders," Food Hydrocolloids
13 (3), 219–225 (1999).
55. C. Confalonieri et al., "The Use of a New Laser Particle Size and Shape Analyser to Detect and Evaluate Gelatinous Microparticles
Suspended in Reconstituted Anthracycline Infusion Solutions," J. Pharm. Biomed. Anal.
9 (1), 1–8 (1991).
56. J.D. Ewing et al., "Evaluating the Reconstitution of Intramuscular Ziprasidone (Geodon) into Solution," Ann. Emergency Med.
43 (3), 427–428 (2004).
57. H. Thiermann et al., "Dissolution Kinetics of Unstable Drugs in Two-Compartment Autoinjectors: Analysis of the Individual
Shaking Behavior and Influence of Various Shaking Parameters on the Dissolution Rate of HI 6 in an Automated System," Int. J. Pharm.
170 (1), 23–32 (1998).
58. S.V. Balasubramanian, "Reconstituion Medium for Protein and Peptide Formulations," US Patent 2005/0069578 (2005).
59. J.T. Carstensen, Physical Testing, J. Swarbrick et al., Eds. (Marcel Dekker Inc., New York 2000), pp. 261–328.
60. K.E. Avis, Sterile Products, L. Lachman, et al., Eds. (Varghese Publishing House, Bombay 1986), p.639–677.
61. F.L. Grab, "Reconstitution of Dry Fill Cyclophosphamide,"US Patent 4775533 (1988).
62. S.A. Quraishi et al., "Dantrolene Reconstitution: Can Warmed Diluent Make a Difference?," J. Clin. Anaesth.
18, 339–342 (2006).
63. C. Allan and R.V. Boccia, "Temperature- and Volume-Dependent Dissolution of Amifostine 500 mg Reconstituted for Subcutaneous
Injection in Normal Saline or Sterile Water for Injection," J. Clin. Oncol. (Meeting Abstracts) 23 (16), 3207 (2005).
64. L.W. Mitchell and B.L. Leighton, "Warmed Diluent Speeds Dantrolene Reconstitution," Can. J. Anaesth.
50 (2), 127–130 (2003).
65. K. Sieunarine and G. H. White, "Full-Thickness Burn and Venous Thrombosis following Intravenous Infusion of Microwave-Heated
Crystalloid Fluids," Burns
22 (7), 568–569 (1996).
|
